i-RNA Corporation

i-RNA Corporation is dedicated to pioneering new methods for the treatment and detection of diabetic retinopathy, marking a significant advancement in pharmaceutical manufacturing. Established as a UWO spin-off, i-RNA Corporation is driven by a commitment to scientific discovery and patient care, focusing on developing innovative gene therapies. The company's approach targets long non-coding RNA HOTAIR, offering a potential treatment for diabetic retinopathy (DR) through both intraocular injections and eye drops. This groundbreaking technology aims to prevent blindness in the working-age population affected by diabetes.

i-RNA Corporation's project is founded on robust scientific data, positioning the company at the forefront of medical innovation. The development of an eye drop treatment for diabetic retinopathy sets i-RNA Corporation apart, addressing a critical unmet need in the market. With its focus on cutting-edge gene therapy, i-RNA Corporation is poised to make a substantial impact on global healthcare, offering new hope for individuals at risk of vision loss due to diabetic retinopathy.

The team at i-RNA Corporation is diligently working to refine and expand its offerings in pharmaceutical manufacturing. The company’s management is actively working to complete further details about i-RNA Corporation. We invite the manager of i-RNA Corporation to create a customized and exclusive company showcase and product listing on our platform to further highlight its capabilities and reach a broader audience.